このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

C-MER Eye Care Holdings 過去の業績

過去基準チェック /26

C-MER Eye Care Holdingsの収益は年間平均-23.6%の割合で減少していますが、 Healthcare業界の収益は年間増加しています。収益は年間5.1% 31.8%割合で増加しています。 C-MER Eye Care Holdingsの自己資本利益率は4.3%であり、純利益率は3.2%です。

主要情報

-23.6%

収益成長率

-28.0%

EPS成長率

Healthcare 業界の成長	11.3%
収益成長率	31.8%
株主資本利益率	4.3%
ネット・マージン	3.2%
前回の決算情報	31 Dec 2023

C-MER Eye Care Holdings' (HKG:3309) Earnings May Just Be The Starting Point

Apr 29

Recent updates

Shareholders Will Probably Hold Off On Increasing C-MER Eye Care Holdings Limited's (HKG:3309) CEO Compensation For The Time Being

May 21

C-MER Eye Care Holdings' (HKG:3309) Earnings May Just Be The Starting Point

Apr 29

C-MER Eye Care Holdings Limited's (HKG:3309) 26% Share Price Plunge Could Signal Some Risk

Feb 02

C-MER Eye Care Holdings (HKG:3309) Might Be Having Difficulty Using Its Capital Effectively

Jan 17

収支内訳

C-MER Eye Care Holdings の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

SEHK:3309 収益、費用、利益 ( )HKD Millions
日付	収益	収益	G+A経費
31 Dec 23	1,924	62	503
30 Sep 23	1,862	28	505
30 Jun 23	1,801	-7	506
31 Mar 23	1,766	-14	489
31 Dec 22	1,732	-22	472
30 Sep 22	1,602	1	445
30 Jun 22	1,473	23	418
31 Mar 22	1,293	22	389
31 Dec 21	1,113	22	361
30 Sep 21	1,036	25	325
30 Jun 21	959	28	289
31 Mar 21	829	11	249
31 Dec 20	700	-6	209
30 Sep 20	636	-10	185
30 Jun 20	573	-13	161
31 Mar 20	575	14	153
31 Dec 19	576	41	145
30 Sep 19	539	53	129
30 Jun 19	502	64	114
31 Mar 19	466	53	103
31 Dec 18	429	43	91
30 Sep 18	396	35	81
30 Jun 18	363	27	71
31 Mar 18	341	31	64
31 Dec 17	311	40	55
30 Sep 17	293	46	48
30 Jun 17	274	52	42
31 Mar 17	267	55	41
31 Dec 16	249	47	38
31 Dec 15	199	38	31
31 Dec 14	156	22	31

質の高い収益: 3309は高品質の収益を持っています。

利益率の向上: 3309過去に利益を上げました。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: 3309の収益は過去 5 年間で年間23.6%減少しました。

成長の加速: 3309は昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。

収益対業界: 3309昨年収益を上げたため、昨年の収益成長をHealthcare業界 ( 7.8% ) と比較することは困難です。

株主資本利益率

高いROE: 3309の自己資本利益率 ( 4.3% ) は低いとみなされます。

C-MER Eye Care Holdings 過去の業績

過去 基準チェック /26

主要情報

最近の業績更新

C-MER Eye Care Holdings' (HKG:3309) Earnings May Just Be The Starting Point

C-MER Eye Care Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

First half 2023 earnings released: EPS: HK$0.024 (vs HK$0.012 in 1H 2022)

C-MER Eye Care Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

Full year 2022 earnings released: HK$0.018 loss per share (vs HK$0.019 profit in FY 2021)

First half 2022 earnings released: EPS: HK$0.012 (vs HK$0.012 in 1H 2021)

Recent updates

Shareholders Will Probably Hold Off On Increasing C-MER Eye Care Holdings Limited's (HKG:3309) CEO Compensation For The Time Being

C-MER Eye Care Holdings' (HKG:3309) Earnings May Just Be The Starting Point

C-MER Eye Care Holdings Limited, Annual General Meeting, May 28, 2024

New major risk - Revenue and earnings growth

C-MER Eye Care Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

C-MER Eye Care Holdings Limited's (HKG:3309) 26% Share Price Plunge Could Signal Some Risk

C-MER Eye Care Holdings (HKG:3309) Might Be Having Difficulty Using Its Capital Effectively

Price target decreased by 12% to HK$4.50

First half 2023 earnings released: EPS: HK$0.024 (vs HK$0.012 in 1H 2022)

C-MER Eye Care Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

C-MER Eye Care Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

C-MER Eye Care Holdings Limited Announces Board Changes, Effective July 3, 2023

Insufficient new directors

Now 21% undervalued after recent price drop

Now 22% undervalued after recent price drop

A Look At The Intrinsic Value Of C-MER Eye Care Holdings Limited (HKG:3309)

Full year 2022 earnings released: HK$0.018 loss per share (vs HK$0.019 profit in FY 2021)

Now 22% undervalued

Capital Allocation Trends At C-MER Eye Care Holdings (HKG:3309) Aren't Ideal

Insufficient new directors

Chairman & CEO recently bought HK$1.9m worth of stock

Chairman & CEO recently bought HK$1.3m worth of stock

Insufficient new directors

Is C-MER Eye Care Holdings (HKG:3309) A Risky Investment?

First half 2022 earnings released: EPS: HK$0.012 (vs HK$0.012 in 1H 2021)

Insufficient new directors

C-MER Eye Care Holdings Limited to Report First Half, 2022 Results on Aug 30, 2022

C-MER Eye Care Holdings Limited, Annual General Meeting, May 24, 2022

Full year 2021 earnings released: EPS: HK$0.019 (vs HK$0.006 loss in FY 2020)

C-MER Eye Care Holdings Limited Recommends No Payment of Any Final Dividend for the Year Ended 31 December 2021

C-MER Eye Care Holdings Limited (SEHK:3309) entered into the Sale and Purchase agreements to acquire Champion Eye Centre Limited from Yeung, Hung, Pauline Chan, Ko, DN Chan,Yip, and the Estate of Cheung for HKD 56.02 million.

Executive Director exercised options to buy HK$1.7m worth of stock.

C-MER Eye Care Holdings Limited (SEHK:3309) entered into an Equity Transfer Agreement to acquire 7% stake in Shenzhen Aikangjian Group Co., Ltd. from Shenzhen Capital Group Co., Ltd. for CNY 45.5 million

First half 2021 earnings released: EPS HK$0.012 (vs HK$0.02 loss in 1H 2020)

C-MER Eye Care Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2021

Independent Non-Executive Director recently bought HK$1.6m worth of stock

C-MER Eye Care Holdings Limited Approves Final Dividend for the Year Ended 31 December 2020

Upcoming dividend of HK$0.02 per share

Full year 2020 earnings released: HK$0.006 loss per share (vs HK$0.04 profit in FY 2019)

Full year 2020 earnings released: HK$0.006 loss per share (vs HK$0.04 profit in FY 2019)

C-MER Eye Care Holdings Limited to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day high: HK$6.89

C-MER Eye Care Holdings Limited (SEHK:3309) signed a Purchase Agreement to acquire 60% stake in CAD/CAM Restorative Dental Centre Limited from YIU Bun Ka for HK$12.9 million.

New 90-day high: HK$6.44

Update: C-MER Eye Care Holdings (HKG:3309) Stock Gained 25% In The Last Year

Independent Non-Executive Director recently bought HK$1.8m worth of stock

C-MER Eye Care Holdings Limited Announces Board Changes

New 90-day low: HK$5.58

Independent Non-Executive Director recently bought HK$208k worth of stock

New 90-day low: HK$5.86

First half earnings released

Independent Non-Executive Director recently bought HK$138k worth of stock

Independent Non-Executive Director recently bought HK$130k worth of stock

First half earnings released

C-MER Eye Care Holdings Limited to Report First Half, 2020 Results on Aug 28, 2020

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /26